Treatment Patterns of Neratinib in HER2+ EBC in China
ConditionBreast Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPierre Fabre Medicament
About this trial
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Eligibility criteria
Qualifiers
Signed written informed consent approved by the reviewing Ethics Committee (EC).
Adult patients (≥18 years of age, no upper limit).
Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or metastatic disease.
Disqualifiers
Presence of any contraindication with regard to the neratinib treatment.
Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).
Trial design
Treatments tested in this trial
- Neratinib
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov